China Pioneer Pharma Holdings Limited
Symbol: 1345.HK
HKSE
1.42
HKDTržní cena dnes
13.7445
Poměr P/E
0.0000
Poměr PEG
1.67B
MRK Cap
- 0.04%
Výnos DIV
China Pioneer Pharma Holdings Limited (1345-HK) finanční výkazy
Rozvaha
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 124.4 | 289 | 402.1 | ||||||||||||
balance-sheet.row.short-term-investments | 0 | 10 | 75 | 177.2 | ||||||||||||
balance-sheet.row.net-receivables | 0 | 448.4 | 413.2 | 251.8 | ||||||||||||
balance-sheet.row.inventory | 0 | 417.9 | 321.1 | 294.9 | ||||||||||||
balance-sheet.row.other-current-assets | 0 | 126.2 | 186.6 | 241.5 | ||||||||||||
balance-sheet.row.total-current-assets | 0 | 1106.9 | 1134.9 | 1013.1 | ||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 247.4 | 221.6 | 91.1 | ||||||||||||
balance-sheet.row.goodwill | 0 | 6.2 | 6.2 | 0 | ||||||||||||
balance-sheet.row.intangible-assets | 0 | 30.2 | 37 | 45.9 | ||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 36.4 | 43.3 | 45.9 | ||||||||||||
balance-sheet.row.long-term-investments | 0 | 117.1 | 156.2 | 82.2 | ||||||||||||
balance-sheet.row.tax-assets | 0 | 2.3 | 8.6 | 12 | ||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 20.7 | -8.6 | -12 | ||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 424 | 421 | 219.2 | ||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 15.8 | 96.1 | ||||||||||||
balance-sheet.row.total-assets | 0 | 1530.9 | 1571.7 | 1328.5 | ||||||||||||
balance-sheet.row.account-payables | 0 | 284.9 | 329.3 | 262 | ||||||||||||
balance-sheet.row.short-term-debt | 0 | 61.3 | 29.6 | 14 | ||||||||||||
balance-sheet.row.tax-payables | 0 | 17.8 | 39.8 | 24.9 | ||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 12.7 | 8 | 0.1 | ||||||||||||
Deferred Revenue Non Current | 0 | 41.4 | 43.6 | 43.6 | ||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||||
balance-sheet.row.other-current-liab | 0 | 0 | 143.5 | 86.2 | ||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 70.4 | 76.3 | 69.3 | ||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 14 | 8.7 | 0.2 | ||||||||||||
balance-sheet.row.total-liab | 0 | 513.1 | 549.2 | 417.5 | ||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 84.1 | 59 | ||||||||||||
balance-sheet.row.common-stock | 0 | 77.4 | 77.4 | 77.6 | ||||||||||||
balance-sheet.row.retained-earnings | 0 | 634.9 | 594.8 | 444.2 | ||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 929 | -84.1 | -59 | ||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | -634.9 | 335.6 | 386.2 | ||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 1006.4 | 1007.8 | 908 | ||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 1530.9 | 1571.7 | 1328.5 | ||||||||||||
balance-sheet.row.minority-interest | 0 | 11.3 | 14.7 | 3 | ||||||||||||
balance-sheet.row.total-equity | 0 | 1017.8 | 1022.5 | 911 | ||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||||||||||
Total Investments | 0 | 117.1 | 231.2 | 259.4 | ||||||||||||
balance-sheet.row.total-debt | 0 | 74 | 37.6 | 14.1 | ||||||||||||
balance-sheet.row.net-debt | 0 | -40.4 | -176.4 | -210.8 |
Výkaz peněžních toků
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 235.3 | 142.6 | 52.4 | |||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 13.6 | 12.9 | 8.4 | |||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.change-in-working-capital | 0 | -193.5 | 226.3 | -147.3 | |||||||||||||
cash-flows.row.account-receivables | 0 | -168 | 66.2 | -65.3 | |||||||||||||
cash-flows.row.inventory | 0 | -25.5 | 160.2 | -82.1 | |||||||||||||
cash-flows.row.account-payables | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.other-working-capital | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.other-non-cash-items | 0 | 37.9 | -139.8 | 160.8 | |||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -74.3 | -16.6 | -34.9 | |||||||||||||
cash-flows.row.acquisitions-net | 0 | -26.7 | -2.4 | -20.9 | |||||||||||||
cash-flows.row.purchases-of-investments | 0 | -717.2 | -2020.3 | -512.9 | |||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 798.1 | 1976.4 | 570.5 | |||||||||||||
cash-flows.row.other-investing-activites | 0 | 7 | 71.4 | 22.1 | |||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -13 | 8.4 | 23.9 | |||||||||||||
cash-flows.row.debt-repayment | 0 | -1.1 | 0 | -0.1 | |||||||||||||
cash-flows.row.common-stock-issued | 0 | 26.9 | 10.4 | -2.8 | |||||||||||||
cash-flows.row.common-stock-repurchased | 0 | -25.8 | -10.3 | -2.8 | |||||||||||||
cash-flows.row.dividends-paid | 0 | -84.7 | -129.9 | -111.9 | |||||||||||||
cash-flows.row.other-financing-activites | 0 | -6.4 | -10.4 | -135.5 | |||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -91 | -140.3 | -253 | |||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | -0.1 | -0.3 | -0.4 | |||||||||||||
cash-flows.row.net-change-in-cash | 0 | -10.8 | 109.8 | -155.3 | |||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 214 | 224.9 | 115 | |||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 224.9 | 115 | 270.3 | |||||||||||||
cash-flows.row.operating-cash-flow | 0 | 93.3 | 242.1 | 74.2 | |||||||||||||
cash-flows.row.capital-expenditure | 0 | -74.3 | -16.6 | -34.9 | |||||||||||||
cash-flows.row.free-cash-flow | 0 | 19 | 225.4 | 39.4 |
Řádek výkazu zisku a ztráty
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 1566.7 | 1556 | 1434.8 | ||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 898.4 | 775.6 | 662.8 | ||||||||||||||
income-statement-row.row.gross-profit | 0 | 668.2 | 780.5 | 772 | ||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||
income-statement-row.row.other-expenses | 0 | 1.6 | 4.8 | 2.7 | ||||||||||||||
income-statement-row.row.operating-expenses | 0 | 488 | 496.6 | 574.6 | ||||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 1386.5 | 1272.1 | 1237.4 | ||||||||||||||
income-statement-row.row.interest-income | 0 | 0.6 | 10.6 | 4 | ||||||||||||||
income-statement-row.row.interest-expense | 0 | 2.5 | 1.7 | 0.9 | ||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | 46.9 | 62.3 | 14.2 | ||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 1.6 | 4.8 | 2.7 | ||||||||||||||
income-statement-row.row.total-operating-expenses | 0 | 46.9 | 62.3 | 14.2 | ||||||||||||||
income-statement-row.row.interest-expense | 0 | 2.5 | 1.7 | 0.9 | ||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 18.9 | 13.2 | 12.7 | ||||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||||||||
income-statement-row.row.operating-income | 0 | 133.5 | 232.2 | 187.2 | ||||||||||||||
income-statement-row.row.income-before-tax | 0 | 180.4 | 294.5 | 201.4 | ||||||||||||||
income-statement-row.row.income-tax-expense | 0 | 51.5 | 64.5 | 60.6 | ||||||||||||||
income-statement-row.row.net-income | 0 | 145.7 | 235.3 | 142.6 |
Často kladené otázky
Co je China Pioneer Pharma Holdings Limited (1345.HK) celková aktiva?
China Pioneer Pharma Holdings Limited (1345.HK) celková aktiva jsou 1530905000.000.
Jaký je roční obrat podniku?
Roční příjmy jsou N/A.
Jaké je ziskové rozpětí podniku?
Zisková marže firmy je 0.427.
Jaký je volný peněžní tok podniku?
Volný peněžní tok je -0.127.
Jaká je čistá zisková marže podniku?
Čistá zisková marže je 0.093.
Jaké jsou celkové tržby podniku?
Celkové příjmy jsou 0.085.
Co je China Pioneer Pharma Holdings Limited (1345.HK) čistý zisk (čistý příjem)?
Čistý zisk (čistý příjem) je 145718000.000.
Jaký je celkový dluh podniku?
Celkový dluh je 74020000.000.
Jaké je číslo provozních nákladů?
Provozní výdaje jsou 488030000.000.
Jaké je číslo peněžních prostředků firmy?
Peněžní prostředky podniku jsou 0.000.